Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcoma
Osteosarcoma (OS) is the most frequent paediatric bone cancer, responsible for 9% of all cancer-related deaths in children. In this paper, a new strategy based on delivering edelfosine (ET) in lipid nanoparticles (LN) was explored in order to target the primary tumor and eliminate metastases. The in vitro and in vivo efficacy of the free drug, drug loaded into lipid nanoparticles (ET-LN) and doxorubicin (DOX) against osteosarcoma (OS) cells was analysed. ET and ET-LN decreased the growth of OS cells in vitro in a time- and dose-dependent manner.
Source: Cancer Letters - Category: Cancer & Oncology Authors: Yolanda Gonz ález-Fernández, Hannah K. Brown, Ana Patiño-García, Dominique Heymann, María J. Blanco-Prieto Tags: Original Articles Source Type: research
More News: Bone Cancers | Cancer | Cancer & Oncology | Children | Nanotechnology | Oral Cancer | Osteosarcoma | Pediatrics